An ambitious project is launched with chronic lymphocytic leukemia patients in the Madrid region
Following the agreement signed between the Madrid Association of Hematology and Hemotherapy (AMHH, according to its Spanish acronym) and Life Length, the trial of clinical validation of the telomeric measurement associated with this disease has begun. The results will serve to evaluate the importance of telomeres as biomarkers in chronic lymphocytic leukemia (CLL) and fostering the creation of the first regional registry of patients with the disease in the Madrid region.
Madrid, May 31, 2017 – Life Length, the leading global healthcare company in the field of telomere diagnostics, and the AMHH, a non-profit organization whose main activity is cooperation to achieve scientific progress in both medical disciplines, have signed a partnership agreement for the implementation of the CLL registry and the implementation by Life Length of telomere measurements related to leukemia. The initiative will involve 29 hospitals in the Madrid region.
Dr. Adrián Alegre, Head of the Hematology Service of Hospital Universitario La Princesa and AMHH president, expressed his satisfaction for this agreement that will boost the work of the different AMHH groups collaborating, such as the CLL group. He commented that similar studies could be applied in other hematological cancers.
The regional registry will contribute to the improvement of medical practice for the diagnosis, follow-up and treatment of CLL. During the first two years of the Life Length registry, it will be carried out an associated study called "Study for measurement of telomere length and telomerase activity as biomarkers of prognosis associated with the regional registry launched for the diagnosis, follow-up and treatment of chronic lymphocytic leukemia (CLL)," to evaluate the importance of telomeres biology as biomarkers in this type of cancer, and its principal investigator will be Dr. José Antonio García Marco, Hospital Universitario Puerta de Hierro.
The study of the biology of telomeres is framed within the ONCOCHECK project which has been funded by the Horizon 2020 research and innovation program of the European Union under funding agreement number 738707 to carry out during two years various clinical studies in children and adults suffering from one of the many existing types of cancer. Its principal objective is to demonstrate the clinical utility as a prognostic biomarker in the treatment of these types of cancer using Life Length’s proprietary technology TAT® (Telomere Analysis Technology®) which can be performed with a simple blood sample.
Stephen J. Matlin, CEO of Life Length, expressed his satisfaction with the agreement, noting that the results of these studies will be very important to continue advancing in "the main objective of this and other projects in which we are actively working that is to improve people’s lives and health, with the full conviction that the telomere biology offers key biomarkers for the most relevant pathologies associated with aging, such as cancer or Alzheimer’s disease."
Life Length: Dr. Pilar Najarro and Stephen J. Matlin (Life Length)
AMHH: Dr. Adrián Alegre Amor, Dr. José Antonio García Marco, Dr. Patricia Baltasar y Dr. Santiago Osorio